Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
72.11
+0.73 (1.02%)
Feb 21, 2025, 4:00 PM EST - Market closed
Incyte Revenue
In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth. Incyte had revenue of $1.18B in the quarter ending December 31, 2024, with 16.32% growth.
Revenue (ttm)
$4.24B
Revenue Growth
+14.76%
P/S Ratio
3.52
Revenue / Employee
$1,680,355
Employees
2,524
Market Cap
13.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
INCY News
- 2 days ago - Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration - Business Wire
- 4 days ago - Incyte to Present at Upcoming Investor Conferences - Business Wire
- 10 days ago - Reevaluating Incyte Corporation After Earnings (Technical Analysis) - Seeking Alpha
- 11 days ago - Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025 - Seeking Alpha
- 11 days ago - Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Incyte reports quarterly sales above estimates on strong demand for key drugs - Reuters
- 12 days ago - Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones - Business Wire
- 14 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire